Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Patel, P. H.
Kondagunta, G. V.
Redman, B. G.
Hudes, G. R.
Kim, S. T.
Chen, I.
Motzer, R. J.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] Pfizer Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5097
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results from a phase I/II study
    Redman, B. G.
    Hudes, G. R.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC).
    Ronnen, E. A.
    Kondagunta, G. V.
    Lau, C.
    Fischer, P.
    Ginsberg, M. S.
    Baum, M.
    Kim, S. T.
    Chen, I.
    Baum, C. M.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 225S - 225S
  • [3] Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Redman, B. G.
    Hudes, G. R.
    Kondagunta, G. V.
    Patel, P. H.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 302 - 302
  • [4] A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
    Wood, Laura S.
    Dreicer, Robert
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ali, Khaled B.
    Haddad, Housam
    Shah, Shetal N.
    Elson, Paul
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Feldman, D. R.
    Kondagunta, G. V.
    Ronnen, E. A.
    Fischer, P.
    Chang, R.
    Baum, M.
    Ginsberg, M. S.
    Ishill, N.
    Patil, S.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Side effects of sunitinib malate (SM) treatment for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Carteni, G. G.
    Montano, M.
    Perrotta, E.
    Otero, M.
    Guida, T.
    Ragone, G.
    Aurilio, G.
    Maiorino, L.
    Stavolo, C.
    Panza, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC)
    Rini, Brian I.
    Wood, Laura S.
    Elson, Paul
    Zhu, Hui
    Chittoria, Namita
    Mittal, Kriti
    Dreicer, Robert
    Gilligan, Timothy D.
    Shah, Shetal N.
    Garcia, Jorge A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Hudes, Gary R.
    Ginsberg, Michelle S.
    Baum, Michael S.
    Harmon, Charles S.
    Kim, Sindy T.
    Chen, Isan
    Redman, Bruce G.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (06): : 614 - 618
  • [9] Continuous daily administration of sunitinib malate (SU11248) - A phase II study in patients (PTS) with cytokine-refractory metastatic renal cell carcinoma (MRCC)
    Escudier, Bernard
    Roigas, Jan
    Gillessen, Silke
    Srinivas, Sandhya
    Pisa, Pavel
    Vogelzang, Nicholas
    Fountzilas, George
    Peschel, Christian
    Baum, Charles M.
    De Mulder, Pieter
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [10] Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC).
    Choueiri, T. K.
    Dreicer, R.
    Rini, B. I.
    Elson, P.
    Garcia, J.
    Mekhail, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 226S - 226S
12345